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Fluoroquinolones are an important class of bacterial type II topoisomerase (DNA gyrase and topoisomerase IV) inhibitors that show broad-spectrum activity and are highly effective in the clinic. In recent years however, the worldwide emergence of fluoroquinolone resistance has raised serious concerns regarding the future utility of this drug class. 4 7 Resistance occurs via a range of mechanisms including target-site gene mutations, overexpression of multi-drug resistance efflux pumps, modifying enzymes and target protection proteins. 8 10 These factors have increased the need to develop new classes of antibiotics that tackle the issue of bacterial resistance. One approach is to identify and explore novel targets with no pre-existing antimicrobial resistance. Issues surrounding target validation along with a lack of physicochemical diversity within screening collections has hindered progress in this area. 11 An alternative approach is to explore clinically validated targets for new compounds that show limited or no cross-resistance to existing antibiotics. This avenue removes the risk of target validation and has been employed effectively within several drug classes. 12 Recent reports have described the use of isothiazoloquinolones and isothiazolopyridones as DNA gyrase inhibitors and some have displayed excellent antimicrobial activity. 13 15 Redx Pharma reports herein the synthesis, structure-activity relationships and in vitro evaluation of a novel class of isothiazolone inhibitors of bacterial type II topoisomerase. A compound from this series has recently been reported to display balanced inhibition of both the supercoiling activity of DNA gyrase and the decatenation function of topoisomerase IV.
The synthetic route to compounds 7a-o was designed to allow the late stage introduction of chemical diversity via manipulation of the chloro substituent within compound 6 (Scheme 1). Starting material 1 was converted to the tert-butyl imine and reacted with triethyl methanetricarboxylate to afford the pyridone 2. Chlorination and subsequent displacement with potassium thioacetate afforded thiol 4. Treatment with hydroxylamine-O-sulfonic acid generated the isothiazolone ring system 5. Trial coupling reactions using intermediate 5 were poor yielding. Protection of the amide groups with TIPS-Cl to afford 6 allowed the coupling reaction to proceed with improved yields. The protecting group was removed during the work up procedure. Regioisomers 8a-c were prepared in a similar fashion from the corresponding isomeric starting materials.
Scheme 1. General synthesis of isothiazolones. Reagents and conditions: (
i) tert-butylamine, Ti(Cl) 4 , DCM, rt, 75% (ii) CH(CO 2 Et) 3 , (Ph) 2 O , 160 o C, 53% (iii) (COCl) 2 , DCM,
Figure 1. Ciprofloxacin
The route to prepare derivative 14 involved incorporation of the indazole at an early stage (Scheme 2). Bromo-indazole 9 was lithiated and treated with N-methoxy-N-methyl butanamide to afford ketone 10. An analogous sequence of steps to Scheme 1 was then followed to afford the final product 14. The antibacterial activity of these compounds was determined against a panel of Gram-positive and Gram-negative bacterial strains including S. aureus, A. baumannii, K. pneumoniae, P. aeruginosa and E. coli from the ESKAPE pathogens. Ciprofloxacin, a fluoroquinolone antibiotic, was also included as a positive control (Figure 1 ). The MICs (Minimum Inhibitory Concentrations), determined as previously described, are reported in Table 1 along with data for the highly sensitive and efflux-deficient ( acrA) E. coli N43 strain. 16, 17 
(Escherichia coli N43). CIP (ciprofloxacin). N.D (Not determined).
Racemic 7a displayed broad-spectrum activity across most strains tested. The stereochemistry of enantiomers 7b and 7c had a limited effect on the activity.
Removal of one or both methyl groups had a pronounced effect on activity as shown by 7d and 7e. Both compounds demonstrated increased potency against E. coli and P. aeruginosa in particular but also suffered a corresponding loss of potency against A. baumannii. This could be attributed to the increased polarity (Table 3) relative to the dimethyl parent compound 7c causing an increased susceptibility to the efflux pump mechanisms of A. baumannii.
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Bicyclic amine analogues gave varying results with both 7f and 7g showing reduced activity. Potency for the 5,6-bicyclic analogue was restored by removal of the methyl group 7h.
In comparison to 7d, homologated analogue 7i displayed reduced activity against all strains except for the E. coli N43 efflux-deficient strain. This suggests 7i may retain potency at the enzyme level but suffer from an increased efflux liability.
Switching from a pyrrolidine ring to a 6-membered piperidine or piperazine was detrimental to activity as shown for 7j, 7k and 7l. The reduced activity against the E. coli N43 strain was considered to be indicative of reduced enzyme activity.
A series of non-basic compounds were prepared and showed retention of activity in many Gramnegative strains. Hydroxyl analogues 7m and 7n retained good activity against S. aureus, E. coli and P. aeruginosa. Difluoro analogue 7o retained reasonable potency against several strains and showed a low efflux ratio between E. coli N43 and its isogenic parent E. coli W4573. Indazole analogue 14 retained broad-spectrum activity.
Meta substitution was detrimental to activity as shown by examples 8a, 8b and 8c. Again, this was attributed to reduced enzyme activity as indicated by the relatively elevated MICs against the effluxdeficient E. coli N43 strain.
Point mutations within the QRDR (quinolone-resistance determining region) of gyrA, gyrB, parC and/or parE are a common source of fluoroquinolone resistance with mutations at S83 and D87 of GyrA being particularly prevalent. 19 Representative compounds, 7a, 7g and 14, were tested against a panel of isogenic laboratory strains of E. coli bearing multiple target specific mutations (e.g. LM693) and efflux mutations (e.g. LM367). 20 All compounds, including ciprofloxacin, displayed a similar fold change reduction in activity against LM625 and LM367 compared to the isogenic parent strain E. coli MG1655 (LM179). However, 7a was observed to show a much less significant decrease in activity against isogenic strains bearing a greater level of mutations (LM693 and LM705) compared to ciprofloxacin. The compounds were further evaluated against a panel of characterised MDR (multidrug resistant) clinical E. coli UTI (urinary tract infection) isolates (CH440, CH460, CH418 and CH448) which also included resistance obtained via horizontal gene transfer. 7a, 7g and 14 all showed a significantly reduced susceptibility to a range of key fluoroquinolone mutations in comparison to ciprofloxacin (Table 2) . However, the elevated MIC values for the tested isothiazolones across both panels exposed an underlying level of fluoroquinolone cross-resistance. Representative compounds were evaluated for in vitro toxicity as shown in Table 3 . No toxic effects were observed in a Hep G2 mammalian cytotoxicity assay for all tested compounds. 7a was measured for hERG inhibition and displayed 84% inhibition at a concentration of 100 µM, with an IC 50 of 20 µM. In line with previous literature reports describing the effects of logD and pKa on hERG inhibition, significant reductions in hERG inhibition were measured for both the more polar analogue 7d and the less basic compound 7n, although subtle structural changes could also be playing a role. 21 23 
